Pay in 4 interest-free payments of $6.87 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Approval Timeline and Availability CagriSema: Ahead in the Race FDA Submission: December 18, 2025 (NDA filed) Expected FDA Decision: Q4 2026 or Q1 2027 Predicted Launch: Mid-2027 Advantage: 6-12 month head start on retatrutide REDEFINE Program Status: REDEFINE-1: Completed (obesity, 20.4% weight loss) REDEFINE-2: Completed (type 2 diabetes, 13.7% weight loss) REDEFINE-3: Ongoing (cardiovascular outcomes trial) REDEFINE-8: Ongoing (body composition study) High-dose CagriSema (2.4/7.2mg): Starting late 2026 Retatrutide: More Trials Needed FDA Submission: Expected Q4 2026 or Q1 2027 Expected FDA Decision: Late 2027 Predicted Launch: Q1-Q2 2028 TRIUMPH Program Status: TRIUMPH-4: Completed (osteoarthritis, 28.7% weight loss) TRIUMPH-1: Complete 28.3% weight loss (May 2026) TRIUMPH-2: Expected Q3Q4 2026 (obesity + type 2 diabetes) TRIUMPH-3: Expected later 2026 (obesity + cardiovascular disease) TRIUMPH-6: Weight maintenance trial (ongoing) Disadvantage: Needs more trials before submission, 6-12 month delay vs CagriSema
If methemoglobinemia is life-threatening, methylene blue administration has still been suggested to be the first-line treatment in G6PD-deficient subjects, starting at a lower dose of 0.3 to 0.5 mg/kg and titrating upward to further reduce methemoglobinemia [14, 20]
Serine hydroxymethyltransferase 2 predicts unfavorable outcomes in multiple cancer: a systematic review and meta-analysis
PepL, consisting of the amino acid sequence Leu-Ser-Leu-Ile-Thr-Arg-Leu, has the unique ability to bind to the interleukin-6 receptor (IL-6R) that is frequently overexpressed in tumor cells (Takeda et al., 2003)
